SI9800046A - Postopek za pridobivanje inhibitorjev HMG-CoA reduktaze visoke čistosti - Google Patents
Postopek za pridobivanje inhibitorjev HMG-CoA reduktaze visoke čistosti Download PDFInfo
- Publication number
- SI9800046A SI9800046A SI9800046A SI9800046A SI9800046A SI 9800046 A SI9800046 A SI 9800046A SI 9800046 A SI9800046 A SI 9800046A SI 9800046 A SI9800046 A SI 9800046A SI 9800046 A SI9800046 A SI 9800046A
- Authority
- SI
- Slovenia
- Prior art keywords
- hmg
- coa reductase
- reductase inhibitor
- broth
- crystallization
- Prior art date
Links
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 title claims abstract description 59
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 title claims abstract description 59
- 238000000034 method Methods 0.000 title claims abstract description 25
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 title claims abstract description 23
- 238000000855 fermentation Methods 0.000 claims abstract description 16
- 230000004151 fermentation Effects 0.000 claims abstract description 16
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 57
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 36
- 238000002425 crystallisation Methods 0.000 claims description 23
- 230000008025 crystallization Effects 0.000 claims description 21
- 239000003960 organic solvent Substances 0.000 claims description 18
- 239000002253 acid Substances 0.000 claims description 15
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 14
- 239000011707 mineral Substances 0.000 claims description 14
- 239000012141 concentrate Substances 0.000 claims description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 238000000605 extraction Methods 0.000 claims description 11
- 238000007273 lactonization reaction Methods 0.000 claims description 9
- 239000000706 filtrate Substances 0.000 claims description 8
- 238000002955 isolation Methods 0.000 claims description 8
- 238000000746 purification Methods 0.000 claims description 8
- 238000005377 adsorption chromatography Methods 0.000 claims description 7
- 238000001914 filtration Methods 0.000 claims description 7
- 239000002028 Biomass Substances 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 239000003814 drug Substances 0.000 abstract description 5
- 238000004519 manufacturing process Methods 0.000 abstract description 5
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract description 4
- 244000005700 microbiome Species 0.000 abstract description 4
- 241000187643 Amycolatopsis Species 0.000 abstract description 3
- 241000228212 Aspergillus Species 0.000 abstract description 3
- 241000228347 Monascus <ascomycete fungus> Species 0.000 abstract description 3
- 241000235395 Mucor Species 0.000 abstract description 3
- 241000187654 Nocardia Species 0.000 abstract description 3
- 241000228143 Penicillium Species 0.000 abstract description 3
- 230000000326 anti-hypercholesterolaemic effect Effects 0.000 abstract description 3
- 241000894007 species Species 0.000 abstract description 3
- 239000008280 blood Substances 0.000 abstract description 2
- 210000004369 blood Anatomy 0.000 abstract description 2
- 230000002265 prevention Effects 0.000 abstract description 2
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 235000012000 cholesterol Nutrition 0.000 abstract 1
- 239000013078 crystal Substances 0.000 description 19
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 16
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 12
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 12
- 229960004844 lovastatin Drugs 0.000 description 12
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 12
- 238000004128 high performance liquid chromatography Methods 0.000 description 10
- 239000000047 product Substances 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 8
- 239000012535 impurity Substances 0.000 description 8
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
- 238000004090 dissolution Methods 0.000 description 4
- 239000002024 ethyl acetate extract Substances 0.000 description 4
- 230000020477 pH reduction Effects 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- CABVTRNMFUVUDM-VRHQGPGLSA-N (3S)-3-hydroxy-3-methylglutaryl-CoA Chemical class O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C[C@@](O)(CC(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 CABVTRNMFUVUDM-VRHQGPGLSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 1
- 241000813221 Aspergillus terreus ATCC 20542 Species 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 1
- AJLFOPYRIVGYMJ-UHFFFAOYSA-N SJ000287055 Natural products C12C(OC(=O)C(C)CC)CCC=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 AJLFOPYRIVGYMJ-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 1
- 239000001099 ammonium carbonate Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 238000001354 calcination Methods 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 238000011026 diafiltration Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- UBHZUDXTHNMNLD-UHFFFAOYSA-N dimethylsilane Chemical compound C[SiH2]C UBHZUDXTHNMNLD-UHFFFAOYSA-N 0.000 description 1
- 238000011038 discontinuous diafiltration by volume reduction Methods 0.000 description 1
- 238000011978 dissolution method Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000003810 ethyl acetate extraction Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- AJLFOPYRIVGYMJ-INTXDZFKSA-N mevastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=CCC[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 AJLFOPYRIVGYMJ-INTXDZFKSA-N 0.000 description 1
- 229950009116 mevastatin Drugs 0.000 description 1
- BOZILQFLQYBIIY-UHFFFAOYSA-N mevastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CCC=C21 BOZILQFLQYBIIY-UHFFFAOYSA-N 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 description 1
- FPLYNRPOIZEADP-UHFFFAOYSA-N octylsilane Chemical compound CCCCCCCC[SiH3] FPLYNRPOIZEADP-UHFFFAOYSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229960002965 pravastatin Drugs 0.000 description 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001223 reverse osmosis Methods 0.000 description 1
- LCHWKMAWSZDQRD-UHFFFAOYSA-N silylformonitrile Chemical compound [SiH3]C#N LCHWKMAWSZDQRD-UHFFFAOYSA-N 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/40—Preparation of oxygen-containing organic compounds containing a carboxyl group including Peroxycarboxylic acids
- C12P7/42—Hydroxy-carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/30—Oxygen atoms, e.g. delta-lactones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/02—Oxygen as only ring hetero atoms
- C12P17/06—Oxygen as only ring hetero atoms containing a six-membered hetero ring, e.g. fluorescein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/62—Carboxylic acid esters
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pyrane Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
- Treatment Of Liquids With Adsorbents In General (AREA)
Priority Applications (23)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SI9800046A SI9800046A (sl) | 1998-02-18 | 1998-02-18 | Postopek za pridobivanje inhibitorjev HMG-CoA reduktaze visoke čistosti |
| JP2000532541A JP2002504345A (ja) | 1998-02-18 | 1999-02-17 | 高純度ＨＭＧ−ＣｏＡレダクターゼ阻害剤の製造方法 |
| PCT/IB1999/000808 WO1999042601A1 (en) | 1998-02-18 | 1999-02-17 | PROCESS FOR THE OBTAINING OF HMG-CoA REDUCTASE INHIBITORS OF HIGH PURITY |
| KR1020007009056A KR100582620B1 (ko) | 1998-02-18 | 1999-02-17 | 고순도의 ＨＭＧ-ＣｏＡ 환원효소 억제제 획득방법 |
| CNB998030805A CN1206363C (zh) | 1998-02-18 | 1999-02-17 | 获得高纯度HMG－CoA还原酶抑制剂的方法 |
| DE69925459T DE69925459T2 (de) | 1998-02-18 | 1999-02-17 | Verfahren zur herstellung von hochreinen hmg-coa reductase inhibitoren |
| YU50100A YU50100A (sh) | 1998-02-18 | 1999-02-17 | Postupak za dobivanje inhibitora hmg-coa reduktaze visoke čistoće |
| HR20000541A HRP20000541A2 (en) | 1998-02-18 | 1999-02-17 | PROCESS FOR THE OBTAINING OF HMG-CoA REDUCTASE INHIBITORS OF HIGH PURITY |
| US09/600,566 US6825015B1 (en) | 1998-02-18 | 1999-02-17 | Process for the obtaining of HMG-COA reductase inhibitors of high purity |
| ROA200000828A RO120922B1 (ro) | 1998-02-18 | 1999-02-17 | PROCEDEU PENTRU OBŢINEREA INHIBITORILOR DE REDUCTAZĂ HMG-CoA |
| CA002321052A CA2321052A1 (en) | 1998-02-18 | 1999-02-17 | Process for the obtaining of hmg-coa reductase inhibitors of high purity |
| IL13778299A IL137782A0 (en) | 1998-02-18 | 1999-02-17 | Process for the obtaining of hmg-coa reductase inhibitors of high purity |
| SI9930812T SI1054993T1 (en) | 1998-02-18 | 1999-02-17 | PROCESS FOR THE OBTAINING OF HMG-CoA REDUCTASE INHIBITORS OF HIGH PURITY |
| PL99342513A PL193510B1 (pl) | 1998-02-18 | 1999-02-17 | Sposób otrzymywania inhibitorów reduktazy HMG-CoAo wysokiej czystości |
| RU2000124064/13A RU2235130C2 (ru) | 1998-02-18 | 1999-02-17 | Способ выделения и способ очистки ингибитора hmg-coa-редуктазы |
| AU34384/99A AU743619B2 (en) | 1998-02-18 | 1999-02-17 | Process for the obtaining of HMG-CoA reductase inhibitors of high purity |
| EP99915976A EP1054993B1 (en) | 1998-02-18 | 1999-02-17 | PROCESS FOR THE OBTAINING OF HMG-CoA REDUCTASE INHIBITORS OF HIGH PURITY |
| HU0100820A HUP0100820A3 (en) | 1998-02-18 | 1999-02-17 | Process for the obtaining of hmg-coa reductase inhibitors of high purity |
| AT99915976T ATE296357T1 (de) | 1998-02-18 | 1999-02-17 | Verfahren zur herstellung von hochreinen hmg-coa reductase inhibitoren |
| SK1185-2000A SK285074B6 (sk) | 1998-02-18 | 1999-02-17 | Spôsob izolácie a čistenia inhibítorov HMG-CoA |
| CZ20002856A CZ297093B6 (cs) | 1998-02-18 | 1999-02-17 | Zpusob izolace a cistení inhibitoru HMG-CoA reduktasy |
| BG104696A BG64289B1 (bg) | 1998-02-18 | 2000-08-17 | М...'од за пол"-аван... на hmg-coa р...д"к'азни инхиби'ори ' ви'ока -и''о'а |
| JP2004372018A JP2005110693A (ja) | 1998-02-18 | 2004-12-22 | ＨＭＧ−ＣｏＡリダクターゼ阻害剤の精製方法、ＨＭＧ−ＣｏＡリダクターゼ阻害剤、および上記方法の使用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SI9800046A SI9800046A (sl) | 1998-02-18 | 1998-02-18 | Postopek za pridobivanje inhibitorjev HMG-CoA reduktaze visoke čistosti |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI9800046A true SI9800046A (sl) | 1999-08-31 |
Family
ID=20432203
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI9800046A SI9800046A (sl) | 1998-02-18 | 1998-02-18 | Postopek za pridobivanje inhibitorjev HMG-CoA reduktaze visoke čistosti |
| SI9930812T SI1054993T1 (en) | 1998-02-18 | 1999-02-17 | PROCESS FOR THE OBTAINING OF HMG-CoA REDUCTASE INHIBITORS OF HIGH PURITY |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI9930812T SI1054993T1 (en) | 1998-02-18 | 1999-02-17 | PROCESS FOR THE OBTAINING OF HMG-CoA REDUCTASE INHIBITORS OF HIGH PURITY |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US6825015B1 (cs) |
| EP (1) | EP1054993B1 (cs) |
| JP (2) | JP2002504345A (cs) |
| KR (1) | KR100582620B1 (cs) |
| CN (1) | CN1206363C (cs) |
| AT (1) | ATE296357T1 (cs) |
| AU (1) | AU743619B2 (cs) |
| BG (1) | BG64289B1 (cs) |
| CA (1) | CA2321052A1 (cs) |
| CZ (1) | CZ297093B6 (cs) |
| DE (1) | DE69925459T2 (cs) |
| HR (1) | HRP20000541A2 (cs) |
| HU (1) | HUP0100820A3 (cs) |
| IL (1) | IL137782A0 (cs) |
| PL (1) | PL193510B1 (cs) |
| RO (1) | RO120922B1 (cs) |
| RU (1) | RU2235130C2 (cs) |
| SI (2) | SI9800046A (cs) |
| SK (1) | SK285074B6 (cs) |
| WO (1) | WO1999042601A1 (cs) |
| YU (1) | YU50100A (cs) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60031447T2 (de) * | 1999-11-30 | 2007-08-30 | Teva Gyogyszergyar Zartköruen Muködo Reszvenytarsasag | Verfahren zur rückgewinnung von statinverbindungen aus einer fermentationsbrühe |
| PL364929A1 (en) | 1999-12-14 | 2004-12-27 | Biogal Gyogyszergyar Rt. | Novel forms of pravastatin sodium |
| HRP20020683A2 (en) * | 2000-02-24 | 2004-12-31 | Biogal Gyogyszergyar | Method of purifying a fermentation broth |
| TR200403001T3 (tr) | 2000-03-03 | 2005-02-21 | Plus Chemical, S.A. | Lovastatin ve simvastatinin, azaltılmış dimerik katışkı seviyelerine sahip olacak şekilde arıtılması için bir işlem |
| IN192861B (cs) * | 2000-06-30 | 2004-05-22 | Ranbaxy Lab Ltd | |
| US6936731B2 (en) * | 2000-10-05 | 2005-08-30 | TEVA Gyógyszergyár Részvénytársaság | Pravastatin sodium substantially free of pravastatin lactone and epi-pravastatin, and compositions containing same |
| JP3236282B1 (ja) | 2000-10-16 | 2001-12-10 | 三共株式会社 | プラバスタチンを精製する方法 |
| US6716615B2 (en) | 2002-02-27 | 2004-04-06 | Yung Shin Pharmaceutical Ind. Co., Ltd. | Strains of saccharaothrix, process for producing pravastatin using the strains and isolation process of (HMG)-CoA reductase |
| US20060019269A1 (en) * | 2002-10-17 | 2006-01-26 | Decode Genetics, Inc. | Susceptibility gene for myocardial infarction, stroke, and PAOD, methods of treatment |
| US20080293750A1 (en) * | 2002-10-17 | 2008-11-27 | Anna Helgadottir | Susceptibility Gene for Myocardial Infarction, Stroke, Paod and Methods of Treatment |
| RU2261901C2 (ru) * | 2003-10-17 | 2005-10-10 | Буяновский Эдуард Константинович | Штамм гриба aspergillus terreus № 44-62 - продуцент ловастатина, промышленный способ выделения ловастатина и способ лактонизации статинов |
| TWI319707B (en) | 2003-11-24 | 2010-01-21 | Method of purifying pravastatin | |
| US20100216863A1 (en) * | 2004-01-30 | 2010-08-26 | Decode Genetics Ehf. | Susceptibility Gene for Myocardial Infarction, Stroke, and PAOD; Methods of Treatment |
| US8158362B2 (en) * | 2005-03-30 | 2012-04-17 | Decode Genetics Ehf. | Methods of diagnosing susceptibility to myocardial infarction and screening for an LTA4H haplotype |
| ES2239533B1 (es) * | 2004-03-01 | 2006-12-16 | Ercros Industrial, S.A. | Procedimiento para la obtencion de compactina. |
| CN102384955B (zh) * | 2010-09-01 | 2014-04-30 | 北京北大维信生物科技有限公司 | 人体血浆中HMG－CoA还原酶抑制剂的定量分析方法 |
| RU2585233C2 (ru) * | 2013-12-27 | 2016-05-27 | Открытое акционерное общество "Красфарма" | Промышленный способ получения компактина |
| RU2585234C2 (ru) * | 2013-12-27 | 2016-05-27 | Открытое акционерное общество "Красфарма" | Способ получения компактина |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4319039A (en) * | 1979-06-15 | 1982-03-09 | Merck & Co., Inc. | Preparation of ammonium salt of hypocholesteremic fermentation product |
| US4294846A (en) * | 1979-09-21 | 1981-10-13 | Merck & Co., Inc. | Hypocholesteremic fermentation products and products of preparation |
| PT85109A (en) | 1986-06-23 | 1987-07-01 | Merck & Co Inc | Process for the preparation of hydroxy-tetrahydropyranone derivatives or corresponding ring opened dihydroxy acids which are hmg-coa reductase inhibitors |
| US4965200A (en) * | 1989-06-23 | 1990-10-23 | Merck & Co., Inc. | Process for the preparation of 3-keto, 5-hydroxy simvastatin analogs |
| US5202029A (en) * | 1991-03-13 | 1993-04-13 | Caron Kabushiki Kaisha | Process for purification of hmg-coa reductase inhibitors |
| ES2145479T3 (es) * | 1995-08-03 | 2000-07-01 | Dsm Nv | Procedimiento mejorado de obtencion de lovastatina, compactina o pravastatina. |
| EA000954B1 (ru) | 1995-12-06 | 2000-08-28 | Балканфарма - Разград Ад | Способ получения ловастатина |
| HUP9902352A1 (hu) | 1999-07-12 | 2000-09-28 | Gyógyszerkutató Intézet Kft. | Eljárás pravasztatin mikrobiológiai előállítására |
-
1998
- 1998-02-18 SI SI9800046A patent/SI9800046A/sl not_active IP Right Cessation
-
1999
- 1999-02-17 RO ROA200000828A patent/RO120922B1/ro unknown
- 1999-02-17 HU HU0100820A patent/HUP0100820A3/hu unknown
- 1999-02-17 WO PCT/IB1999/000808 patent/WO1999042601A1/en active IP Right Grant
- 1999-02-17 YU YU50100A patent/YU50100A/sh unknown
- 1999-02-17 CN CNB998030805A patent/CN1206363C/zh not_active Expired - Fee Related
- 1999-02-17 AT AT99915976T patent/ATE296357T1/de active
- 1999-02-17 DE DE69925459T patent/DE69925459T2/de not_active Expired - Lifetime
- 1999-02-17 CZ CZ20002856A patent/CZ297093B6/cs not_active IP Right Cessation
- 1999-02-17 IL IL13778299A patent/IL137782A0/xx not_active IP Right Cessation
- 1999-02-17 PL PL99342513A patent/PL193510B1/pl unknown
- 1999-02-17 EP EP99915976A patent/EP1054993B1/en not_active Expired - Lifetime
- 1999-02-17 JP JP2000532541A patent/JP2002504345A/ja active Pending
- 1999-02-17 RU RU2000124064/13A patent/RU2235130C2/ru not_active IP Right Cessation
- 1999-02-17 HR HR20000541A patent/HRP20000541A2/xx not_active Application Discontinuation
- 1999-02-17 SI SI9930812T patent/SI1054993T1/xx unknown
- 1999-02-17 KR KR1020007009056A patent/KR100582620B1/ko not_active Expired - Fee Related
- 1999-02-17 US US09/600,566 patent/US6825015B1/en not_active Expired - Fee Related
- 1999-02-17 AU AU34384/99A patent/AU743619B2/en not_active Ceased
- 1999-02-17 SK SK1185-2000A patent/SK285074B6/sk not_active IP Right Cessation
- 1999-02-17 CA CA002321052A patent/CA2321052A1/en not_active Abandoned
-
2000
- 2000-08-17 BG BG104696A patent/BG64289B1/bg unknown
-
2004
- 2004-12-22 JP JP2004372018A patent/JP2005110693A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN1206363C (zh) | 2005-06-15 |
| AU743619B2 (en) | 2002-01-31 |
| JP2002504345A (ja) | 2002-02-12 |
| PL342513A1 (en) | 2001-06-18 |
| BG104696A (en) | 2001-07-31 |
| BG64289B1 (bg) | 2004-08-31 |
| DE69925459T2 (de) | 2006-04-27 |
| SK11852000A3 (sk) | 2001-05-10 |
| KR20010041024A (ko) | 2001-05-15 |
| CN1291238A (zh) | 2001-04-11 |
| US6825015B1 (en) | 2004-11-30 |
| CZ20002856A3 (cs) | 2000-11-15 |
| EP1054993B1 (en) | 2005-05-25 |
| PL193510B1 (pl) | 2007-02-28 |
| SI1054993T1 (en) | 2005-10-31 |
| RO120922B1 (ro) | 2006-09-29 |
| HUP0100820A3 (en) | 2003-07-28 |
| DE69925459D1 (de) | 2005-06-30 |
| WO1999042601A1 (en) | 1999-08-26 |
| JP2005110693A (ja) | 2005-04-28 |
| CA2321052A1 (en) | 1999-08-26 |
| EP1054993A1 (en) | 2000-11-29 |
| RU2235130C2 (ru) | 2004-08-27 |
| KR100582620B1 (ko) | 2006-05-23 |
| AU3438499A (en) | 1999-09-06 |
| ATE296357T1 (de) | 2005-06-15 |
| SK285074B6 (sk) | 2006-05-04 |
| CZ297093B6 (cs) | 2006-09-13 |
| YU50100A (sh) | 2003-07-07 |
| HUP0100820A2 (hu) | 2001-08-28 |
| HRP20000541A2 (en) | 2001-12-31 |
| IL137782A0 (en) | 2001-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI9800046A (sl) | Postopek za pridobivanje inhibitorjev HMG-CoA reduktaze visoke čistosti | |
| EP0702679B1 (en) | Process for the isolation of lovastatin | |
| AU2001236543B2 (en) | Method of purifying a fermentation broth | |
| WO1994029292A9 (en) | Process for the isolation of lovastatin | |
| AU2001236543A1 (en) | Method of purifying a fermentation broth | |
| WO2001039768A1 (en) | Process for recovering statin compounds from a fermentation broth | |
| US6268186B1 (en) | HMG-CoA reductase inhibitor preparation process | |
| KR20030042018A (ko) | 프라바스타틴의 정제 방법 | |
| CN108101802A (zh) | 一种高纯度替加环素的精制方法 | |
| NO137969B (no) | Fremgangsm}te for isolering og rensning av antifungalt aktive forbindelser | |
| HK1071522A (en) | Process for recovering statin compounds from a fermentation broth | |
| EP1798214A1 (en) | Process for recovering statin compounds from a fermentation broth |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| IF | Valid on the event date | ||
| KO00 | Lapse of patent |
Effective date: 20080825 |